<DOC>
	<DOCNO>NCT01488019</DOCNO>
	<brief_summary>This study multi-center , randomize , placebo-controlled study evaluate long-term safety Perforomist® inhalation therapy subject Chronic Obstructive Pulmonary Disease ( COPD ) . Individual participation approximately 54 week , include 52 week double-blind treatment .</brief_summary>
	<brief_title>Study Evaluate Safety Long-Term Use Perforomist® ( Formoterol Fumarate )</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Able understand study requirement , provide write informed consent , agree abide study protocol restriction 2 . Male female subject least 40 year age medical diagnosis COPD ( i.e . persistent presence dyspnea , cough sputum production history exposure risk factor disease , tobacco smoke ) 3 . A current prior history least 10 packyears cigarette smoke baseline breathlessness severity grade &gt; =2 ( Modified Medical Research Council [ MMRC ] Dyspnea Scale Score ) randomization . 4 . Women childbearing potential ( WOCBP ) must negative pregnancy test screen visit agree avoid become pregnant duration study use adequate contraception study entry throughout trial . WOCBP advise notify Investigator change pregnancy status . WOCBP include : female experience menarche postmenopausal ( define amenorrhea least 12 consecutive month ) , undergone surgical sterilization ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) . Women use acceptable contraceptive medication device prevent pregnancy practice abstinence partner sterile ( e.g. , vasectomy ) consider WOCBP . 5 . Able complete aspect study end study , include visit test , selfadministration study medication . 1 . A medical diagnosis asthma . Indication past history asthma deem inaccurate subject 's current condition Investigator must adequately addressed medical history . 2 . Clinically significant abnormal chest xray ( CXR ) ( within past 12 month ) diagnostic active/significant disease COPD . 3 . Evidence unstable clinically significant hematopoietic , malignant , cardiovascular , hepatic , renal , neurologic , psychiatric , autoimmune disorder , condition disease COPD , opinion Investigator , could place subject increase risk complication , interfere study participation , confound study objective . 4 . Subjects radiation chemotherapy within previous 12 month . 5 . An abnormal laboratory test screening deem clinically significant exclusionary Investigator . 6 . A history hypersensitivity study drug component , include albuterol rescue .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>